BioCryst Botched Flu Results (BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has announced preliminary findings from a Phase II study with intramuscular injection of Peramivir, the Company's product candidate for the treatment of seasonal and life-threatening ...Read Full Story »

